SCHEMBL6845166

SCHEMBL6845166

Cc1ccc2c(n1)CC[C@@H]2N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.37
DRD1 P21728 1/20 0.37
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK4 Q16654 1/20 0.33
CCR1 P32246 2/20 0.32
RAB9A P51151 1/20 0.32
CCR5 P51681 1/20 0.32
CYP2C19 P33261 1/20 0.32
CCR8 P51685 1/20 0.31
ACHE P22303 1/20 0.31
HCRTR1 O43613 2/20 0.31
HCRTR2 O43614 2/20 0.31
ALDH1A1 P00352 1/20 0.30
MAPK1 P28482 1/20 0.30
HTT P42858 1/20 0.30
CACNA1B Q00975 1/20 0.30
APBA1 Q02410 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6845212 1.00 DRD2 (0.37) DRD2DRD1NOS3NOS2PDK2
Hydrochloric Acid SCHEMBL12984429 0.98 DRD2 (0.36) DRD2DRD1NOS3NOS2PDK2
Hydrochloric Acid SCHEMBL1915444 0.98 DRD2 (0.36) DRD2DRD1NOS3NOS2PDK2
SCHEMBL18816757 0.78 CHRNB2 (0.41) DRD2ACHE
SCHEMBL18794973 0.78 CHRNB2 (0.41) DRD2ACHE
SCHEMBL10238794 0.78 DRD2 (0.38) DRD2DRD1NOS3NOS2PDK2
SCHEMBL6845116 0.78 DRD2 (0.38) DRD2DRD1NOS3NOS2PDK2
SCHEMBL21223419 0.77 DRD2 (0.37) DRD2DRD1PDK2PDK4CCR1
SCHEMBL21223232 0.77 GRM5 (0.41) DRD2DRD1PDK2PDK4CCR1
Hydrochloric Acid SCHEMBL20538830 0.77 CHRNB2 (0.40) DRD2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742106-B2 Disubstituted heteroaryl-fused pyridines NOVARTIS AG (CH) 2014-06-03 US disclosed
US-8742106-B2 Disubstituted heteroaryl-fused pyridines NOVARTIS AG (CH) 2014-06-03 US disclosed
EP-2516437-B1 DISUBSTITUTED HETEROARYL-FUSED PYRIDINES NOVARTIS AG (CH) 2014-01-29 EP disclosed
CN-102762560-A Disubstituted heteroaryl-fused pyridines NOVARTIS AG 2012-10-31 CN disclosed
US-20120258973-A1 DISUBSTITUTED HETEROARYL-FUSED PYRIDINES NOVARTIS AG (CH) 2012-10-11 US disclosed
US-20120258973-A1 DISUBSTITUTED HETEROARYL-FUSED PYRIDINES NOVARTIS AG (CH) 2012-10-11 US disclosed
WO-2011076744-A1 DISUBSTITUTED HETEROARYL-FUSED PYRIDINES NOVARTIS AG (CH) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258973-A1 DISUBSTITUTED HETEROARYL-FUSED PYRIDINES CYP4F2, CYP11B2, CYP4F3 DRD2 808/4885DRD1 1359/4885NOS3 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.